Despite strong revenue, the low P/S ratio may be due to less attractive future growth rates. Investors pay less for the stock, expecting limited growth rates to persist. Unless medium-term conditions improve, they will continue to limit the share price.
聯康生物科技集團股票討論區
暫無評論